Your browser doesn't support javascript.
loading
Dyslipidemia.
Arvanitis, Marios; Lowenstein, Charles J.
Afiliação
  • Arvanitis M; Johns Hopkins University School of Medicine, Baltimore, Maryland (M.A., C.J.L.).
  • Lowenstein CJ; Johns Hopkins University School of Medicine, Baltimore, Maryland (M.A., C.J.L.).
Ann Intern Med ; 176(6): ITC81-ITC96, 2023 06.
Article em En | MEDLINE | ID: mdl-37307585
ABSTRACT
Dyslipidemia is an important risk factor for coronary artery disease and stroke. All persons with dyslipidemia should be advised to focus on lifestyle interventions, including regular aerobic exercise, a healthy diet, maintenance of a healthy weight, and abstinence from smoking. In addition to lifestyle interventions, lipid-lowering therapy should be considered for persons at moderate to high risk for atherosclerotic cardiovascular disease based on validated risk equations. Statin therapy is the first-line medical treatment for dyslipidemia due to its effectiveness and favorable adverse effect profile, but newer treatments provide additional tools for clinicians to effectively treat dyslipidemia.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose / Dislipidemias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose / Dislipidemias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article